Invention Grant
US08455625B2 Fusion protein of antibody L19 against fibronectin ED-B and interleukin 12
有权
抗体L19抗纤连蛋白ED-B和白细胞介素12的融合蛋白
- Patent Title: Fusion protein of antibody L19 against fibronectin ED-B and interleukin 12
- Patent Title (中): 抗体L19抗纤连蛋白ED-B和白细胞介素12的融合蛋白
-
Application No.: US11913483Application Date: 2006-05-03
-
Publication No.: US08455625B2Publication Date: 2013-06-04
- Inventor: Dario Neri , Verena Gafner , Cornelia Halin
- Applicant: Dario Neri , Verena Gafner , Cornelia Halin
- Applicant Address: IT Siena
- Assignee: Philogen S.p.A.
- Current Assignee: Philogen S.p.A.
- Current Assignee Address: IT Siena
- Agency: Dann, Dorfman, Herrell and Skillman, P.C.
- Agent Patrick J. Hagan
- International Application: PCT/EP2006/004114 WO 20060503
- International Announcement: WO2006/119897 WO 20061116
- Main IPC: C07K16/30
- IPC: C07K16/30 ; C07K16/46 ; C07K14/54 ; C07H21/04 ; C12N5/16 ; C12N1/21 ; C12N15/63 ; C12N15/24 ; A61P35/00

Abstract:
Conjugate for targeting therapeutic or diagnostic agent or drug to cells or tissues in a body, e.g. areas of neoplastic growth or angiogenesis. Use of conjugate for in vivo diagnosis or therapy e.g. inhibiting tumor growth or metastasis, inhibiting angiogenesis and/or treating cancer. Conjugate comprises therapeutic or diagnostic agent as oligomeric protein e.g. heterodimeric protein, wherein first and second subunits of protein are each conjugated to a specific binding member e.g. an antibody fragment such as scFv. Subunits of oligomer may be conjugated to specific binding members as fusion proteins. Conjugate may comprise IL-12 heterodimer having two subunits, each subunit fused to scFv L19 or TN11 for targeting IL-12 to extracellular matrix components associated with neoplastic growth and angiogenesis.
Public/Granted literature
- US20090035255A1 CONJUGATE FOR TARGETING OF DRUG Public/Granted day:2009-02-05
Information query